

2022 ANNUAL REPORT

amfAR, The Foundation
for AIDS Research

amfAR
MAKING AIDS HISTORY

One person dies of
AIDS-related illnesses

EVERY
MINUTE
**THE FIGHT
IS NOT OVER**

OUR MISSION



amfAR, The Foundation
for AIDS Research, is dedicated to
ending the global AIDS epidemic
through innovative research.

CONTENTS → → →

06 TOWARD A CURE

07 RESEARCH

14 PUBLIC POLICY

18 TREAT ASIA

23 PUBLIC INFORMATION

26 GRANTS, FELLOWSHIPS, AND AWARDS

27 RESEARCH GRANTS, FELLOWSHIPS, AND AWARDS

27 TREAT ASIA GRANTS AND AWARDS

30 PUBLIC POLICY GRANTS AND AWARDS

31 FINANCIAL SUMMARY

34 LEADERSHIP AND ADVISORY COMMITTEES

35 BOARD OF TRUSTEES

35 SCIENTIFIC ADVISORY COMMITTEE

38 PROGRAM ADVISORY COUNCIL

38 MANAGEMENT GROUP

FROM THE CO-CHAIRS → →

Dear Friend of amfAR,

This overview of amfAR's activities and achievements in 2022 reflects our unwavering determination to eliminate HIV/AIDS as a global health threat through innovative research.

That research is conducted by dedicated scientists in labs and clinics in the U.S. and around the world inching ever closer to a cure for HIV. It is conducted by our advocacy team, working tirelessly to show what's working and what isn't working, to pinpoint needs and gaps, and to guide policies and practices. And it's conducted by the physicians, biostatisticians, and others on the front lines of our TREAT Asia program, investigating the intersections of HIV, mental health, hepatitis, tuberculosis, and other conditions.

Our work and the need for solutions remain as urgent as ever. One person dies of AIDS-related causes every minute and three others become infected with HIV. In 2021, AIDS claimed the lives of 100,000 children. And a quarter of those living with HIV—roughly 10 million people—still don't have access to lifesaving treatment.

However, the reasons to be hopeful increase with every new case of a cure (five so far), with every research breakthrough, and with every advance in treatment and prevention. And they increase with every generous gift, large or small, in support of our work.

Five decades into the AIDS pandemic, we are heartened and profoundly grateful that you and so many others remain with us on this arduous journey. With your continued support, we are confident that, together, we'll make AIDS history.



T. Ryan Greenawalt
Co-Chair of the Board of Trustees

Kevin McClatchy
Co-Chair of the Board of Trustees

**TOWARD
A CURE**

RESEARCH → → →

Close to 40 million people worldwide are living with HIV. And while access to lifesaving antiretroviral drugs has improved health outcomes for many, AIDS still claims a life every minute. New infections have steadily decreased but are on the rise in regions like Eastern Europe and Central Asia. To end AIDS once and for all, we need a cure. And the only way to reach that goal is through the cutting-edge research that has been amfAR's hallmark since 1985.

85.6 MILLION

Total number of HIV infections since beginning of pandemic



Two new cases of HIV cure via stem cell transplant—the New York and City of Hope patients—were reported in 2022. While this was welcome news, stem cell transplantation remains a high-cost, high-risk procedure that is not scalable for the 39 million people living with HIV. Nevertheless, much can be learned from these cases about what it takes to eliminate the HIV reservoir. Meanwhile, amfAR researchers are exploring a range of innovative approaches to developing a cure that could be made available to all who need it.

ADVANCING HIV CURE STRATEGIES

amfAR Cure Trial

A complex, multi-stage clinical trial—the culmination of five years of work by teams of researchers at the amfAR Institute for HIV Cure Research—is currently underway at the University of California, San Francisco (UCSF). The potentially groundbreaking trial, led by Dr. Steven G. Deeks, principal investigator at the amfAR Institute, is testing a combination of agents in an effort to induce post-treatment control in people living with HIV.

Probing the HIV Reservoir

amfAR grantees are using high-tech tools to probe the HIV reservoir, the main barrier to a cure, and pinpoint its vulnerabilities.

High-tech imaging: In order to target and potentially eradicate the HIV reservoir, scientists first need to discover where exactly HIV hides out. amfAR grantee Dr. Timothy Henrich and

colleagues at the amfAR Institute recently became the first to develop a method of using PET (positron emission tomography) imaging to directly assess which tissues in live humans harbor the greatest burden of HIV. The researchers also described the shifting location of the reservoir over the course of long-term treated HIV and new methods of measuring HIV activity inside lymph nodes, intestines, and, notably, nasal passages in real time. Findings were published in the prestigious journal *Nature Communications*.



“One thing that we are learning more and more is to never underestimate the power of the immune system.”

– amfAR grantee Mathias Lichterfeld, M.D., Ph.D.

The not-so-latent reservoir: Researchers traditionally refer to the reservoir of HIV that persists despite antiretroviral therapy (ART) as “latent.” This refers to observations suggesting that, while a person takes ART, there is minimal production of new viruses. However, ART does not affect the ability of viruses to produce RNA, an intermediate step to the generation of new viruses.



Dr. Jerome Zack

A team of researchers led by amfAR grantee Dr. Mathias Lichterfeld, of Brigham and Women's Hospital in Boston, has developed a method to simultaneously probe the site at which the virus is integrated into the DNA—whether or not it is genetically intact—and its production of RNA.

As described in *Cell*, the researchers used a new assay to characterize the reservoirs of six people living with HIV (PLWH) on long-term ART. They concluded that rather than being stable or “latent,” the immune system may continuously detect and eliminate reservoir cells that produce RNA—even in people taking ART—and that these forces may result in an increasingly defective collection of viruses that hide in regions of DNA from which they cannot emerge.

Silencing factors: There is currently limited knowledge of the mechanisms by which expression of viral proteins is blocked in HIV reservoir cells. Using gene-editing technology based on CRISPR, a team led by amfAR grantee Dr. Ya-Chi Ho identified 18 possible silencing factors. As described in *Journal of Virology*, they focused on one, SLTM, not previously known to affect HIV growth. Knocking down the gene encoding SLTM increased HIV expression more than fourfold in T-cell lines. Using CD4+ T cells derived directly from 10 people living with HIV on ART, they also demonstrated that suppressing SLTM induced death of the HIV-infected cells.

Under the microfluidic microscope: At the 2022 International AIDS Conference, amfAR grantee Dr. Eli Boritz described a microfluidic technology many years in the making that was used to sort single infected cells out from the bulk of (uninfected) blood cells, so that each infected cell could be individually interrogated. His team found that the genetic programming of infected cells was altered so that the cells were more likely to survive, more likely to proliferate, and less likely to produce virus, helping them evade detection by the immune system.

Can “Shock and Kill” Be Revived?

One of the most studied HIV cure strategies is the so-called “shock and kill” approach, in which dormant HIV is “shocked” by a latency-reversing agent (LRA) into making copies of itself and thus alerting the immune system to its presence, while boosting the ability of the immune system to kill infected cells. There is a long history of attempts at “shock and kill” that have met with limited success. On the one hand, the “shock” arm of the strategy has been either safe but ineffective, or effective but unsafe. In addition, the “kill” arm has been at best only moderately effective.

To test whether these components would work better in combination, a group of researchers led by amfAR grantees Dr. Michel Nussenzweig and Ole Sogaard tested the putative LRA romidepsin with the antibody 3BNC117. The clinical trial, named





ROADMAP, included 20 participants. Nine were treated with romidepsin alone while the other 11 were treated with romidepsin and 3BNC117. Disappointingly, neither group showed a clinically meaningful delay to rebound.

However, another amfAR-funded study, published in January 2022, suggests that it may be premature to jettison the “shock-and-kill” approach. Reported in *Nature Communications*, Dr. Jerome Zack, of UCLA, and his team used an innovative tweak to the approach. Dr. Zack created an analog of a potent LRA, bryostatin, which is otherwise toxic for human use, called SUW133, known to be able to induce the death of a subset of HIV-infected cells. The researchers combined SUW133 with a kill agent in the form of natural killer cells and tested it in humanized mice. Four out of the 10 mice treated with the combination experienced no rebound of HIV, providing renewed promise that “shock and kill” can be refined and potentially revived.

Developing Next-Generation COVID Vaccines

Use of mRNA technology in the design of vaccines against SARS-CoV-2, the virus that causes COVID-19, revolutionized the response to this infection. But newer strains of virus resistant to the original vaccines illustrate the need to reconfigure these products.

Now researchers working in the U.S. and Europe, including amfAR Mathilde Krim Fellow Dr. Aleksandar Antanasijevic, have used similar technology to focus on a part of the S protein known as RBD, which is the target for 90% of the

virus-neutralizing antibodies present in recovering COVID-19 patients. They constructed a flexible, nanoparticle-based vaccine that protected genetically engineered mice against the SARS-CoV-2 Delta variant.

Dr. Antanasijevic was also a member of a team that analyzed blood samples collected before the COVID pandemic, and from people recovering from COVID. Pre-pandemic samples commonly harbored antibodies against other coronaviruses linked to the common cold. Blood from people recovering from current pandemic strains of coronavirus had increases in antibodies to non-COVID-19 coronaviruses. The researchers suggested two possible explanations, both of which point to similarities between common cold coronaviruses and the COVID coronavirus.

SUPPORTING CUTTING-EDGE RESEARCH

Target Grants

In March 2022, amfAR awarded a \$100,000 grant to Anjie Zhen, Ph.D., of the University of California, Los Angeles, who is trying to determine if chimeric antigen receptor (CAR) T cell therapy, which has been successful in cancer treatment, could be a way to eliminate HIV in a patient’s body. CAR T cells are genetically altered to seek out and destroy pathogens such as cancer or HIV, but they have been less successful in the treatment of HIV in large part because over time they become exhausted and ineffective.



“amfAR’s Mathilde Krim Fellowship has played a critical role in my development as an independent scientist and helped me fulfill my life’s dream of becoming a professor.”

– Aleksandar Antanasijevic, Ph.D., Mathilde Krim Fellow

Dr. Zhen’s previous study found that autophagy—the natural process through which the body cleans debris out of cells—can both enhance the ability of CAR T cells to fight HIV and reduce the toxicity of latency-reversing agents used to force HIV out of hiding. Dr. Zhen and her team plan to identify the most effective autophagy-inducing drugs and use them in combination with CAR T cells and an LRA in an effort to eliminate HIV infection. She was also awarded an ARCHE grant later in the year (see below).

In June, Qigui Yu, M.D., Ph.D., of Indiana University, was awarded a \$100,000 grant to test a class of drugs approved to treat cancer to eradicate HIV-infected T follicular helper (Tfh) cells. Tfh cells usually function to educate B cells in making the most appropriate antibodies to fight infection. But when HIV-infected, Tfh cells may play a significant role in spreading infection, given their position in the lymph node, in proximity to other immune cells. Dr. Yu is testing several compounds in a class of drugs that inhibit the protein BIRC5, whose usual function is to keep cells alive, and see if these BIRC5 inhibitors will allow infected Tfh cells to die.

ARCHE Grants

Several grants were awarded through the amfAR Research Consortium on HIV Eradication, or

“I am particularly fascinated by elite controllers, who can serve as a model for what a cure of HIV infection may look like.”

– amfAR grantee Xu Yu, M.D.



ARCHE, launched in 2010 to support collaborative research initiatives aimed at curing HIV.

Xu Yu, M.D., of Massachusetts General Hospital in Boston, received a \$1 million grant to explore how ART may contribute to an HIV cure. Dr. Yu is studying 50 people who have been on ART for at least 15 years and will describe the loss of replication-competent viruses and relative accumulation of viruses in so-called “gene deserts” to determine if HIV has been cleared. Dr. Yu and her team previously helped confirm initial findings in the case of a woman, named the Esperanza



amfAR grantee Dr. Anjie Zhen (center) with her research team (L-R): Wally Wennerberg, Hwee Ng, Dr. Li Wang, Nicholas Tien, Dr. Caitlin Kan, and Dr. Shallu Tomer



40.4 MILLION

Cumulative total deaths from AIDS-related illnesses



patient, who has apparently cleared HIV capable of producing progeny without the help of ART.

Saar Gill, Ph.D., of the University of Pennsylvania in Philadelphia, received \$180,000 to design a transplant intervention for individuals living with HIV using a person's own gene-edited cells. Before the transplant, Dr. Gill plans a series of immunotherapy and gene therapy interventions that would eliminate most or perhaps all of the viral reservoir. The transplanted cells will be gene-edited to protect them from HIV infection. After the transplant, he will use CAR T cell immunotherapy to help clear out the remainder of the original immune system, which might still harbor HIV. This process will be tested in a small animal model.

With a \$148,500 grant, Keith Jerome, M.D., Ph.D., of the University of Washington in Seattle, is studying whether or not the presence of ART might adversely impact the efficacy of one of the most widely used means of delivering gene therapy—adeno-associated virus (AAV). Individuals who receive gene therapy most likely will be taking ART, so the question of compatibility is a vital one.

Anjie Zhen, Ph.D. (see above), is using a \$210,000 ARCHE grant to continue to fine-tune CAR T cell therapy as a means of curing HIV. Dr. Zhen is using blood-derived stem cells, selected for their potential to persist and self-renew. She will explore their capacity to mature into not only CAR T cells, but also CAR-natural killer cells and CAR-macrophages, all three of which have the potential to attack HIV-infected cells.

Mathilde Krim Fellowships

The recipients of the 2022 Mathilde Krim Fellowships in Biomedical Research—Sebastian Fuchs, Ph.D., of the University of Miami in Florida, Leila Giron, Ph.D., of The Wistar Institute in Philadelphia, and Jeannette Tenthorey, Ph.D.,

of the Fred Hutchinson Cancer Research Center in Seattle—were each awarded approximately \$150,000 over two years. Named for amfAR's Founding Chairman, the Krim Fellowships provide much-needed support to talented young investigators, who may become the HIV research leaders of tomorrow.

Dr. Fuchs and his mentor Dr. Ron Desrosiers have been working on a gene therapy approach to delivering the instructions for making specific antibodies so that a person's body could make an indefinite supply of them. One challenge is that the immune system can generate responses against these antibodies and destroy them before they can exert their beneficial effects. Dr. Fuchs is attempting to induce immune tolerance of the foreign antibodies by either repeatedly exposing the immune system to the antibodies themselves, or by recruiting red blood cells to convey a



*"The beauty is, one shot
and you're good for life—
that's the goal."*

— Mathilde Krim Fellow Dr. Sebastian Fuchs on a gene therapy approach that would enable the body to create antibodies to prevent HIV infection and/or cure HIV.



Dr. Leila Giron

message of tolerance to the immune system. His results may improve our ability to deliver antibodies as therapy not only for HIV, but across a wide range of diseases.

Dr. Giron has data suggesting the process of cell metabolism can affect the ability of HIV to reactivate, and that some components of the process can even predict whether, and for how long, a person can control HIV without ART. She plans to delve into the relationship between this metabolic process and the ability to control HIV.

Dr. Tenthorey's research focuses largely on TRIM5alpha, an antiviral protein that restricts HIV. Dr. Tenthorey will investigate further the process through which TRIM5alpha binds to HIV and alters the uncoating process necessary for a virus to infect a cell. While HIV has evolved to avoid the action of TRIM5alpha, better understanding this process could lead to therapies that would allow the human body to block the virus.

SHARING KNOWLEDGE

Published Research

amfAR is a leading voice in the scientific conversation pertaining to HIV, as evidenced by the many amfAR-funded research studies published in peer-reviewed journals. In FY2022, 29 scientific publications resulted from amfAR-funded research. Highlights include:

Tracing the Unique Immune Footprints of Elite Controllers

Continuing on their theme of ART-free control of HIV, Drs. Mathias Lichterfeld and Xu Yu (see pages 9, 11) studied the integrated proviruses of elite controllers and compared them to patterns seen among people on ART. Publishing their findings in *Science Translational Medicine*, they found evidence that in ECs, but to a far lesser extent in ART-treated PWH, proviruses tend to accumulate in gene deserts, making them less likely to reactivate and thus making ART-free control easier.

Identifying New Targets in Host Cells to Attack HIV

HIV could not function without hijacking multiple pathways involved in the growth and functioning of the host cell it infects. Yet attempts to identify the specific factors involved in this interaction, using standard genetic and biochemical tests, have yielded very few important targets that affect viral function. Two amfAR Krim Fellows, Drs. Judd Hultquist and Ujjwal Rathore, teamed up with others to examine 364 genes that had previously been implicated as important to the lifecycle of HIV. The authors concluded that their strategy may serve as a roadmap for host factor discovery and potential intervention, not only for HIV but for other emerging or under-studied infections as well. Findings were published in *Nature Communications*.

PUBLIC POLICY →

Ever since amfAR's Founding International Chairman Elizabeth Taylor and Founding Chairman Dr. Mathilde Krim testified before Congress on the urgent need for a robust federal response to AIDS, amfAR has been an influential advocate, fighting for evidence-based public health policies and adequate funding for research, prevention, treatment, and services for people living with HIV. Today, with the LGBTQ community and reproductive health programs—which often include testing and other essential HIV services—under siege and funding for domestic and international HIV programs under threat, amfAR's advocacy is as important as ever.

2 new HIV infections occur

EVERY MINUTE

ADDRESSING PUBLIC HEALTH EMERGENCIES

In 2022, amfAR's public policy office addressed the challenges presented by national and global syndemics—synergistic epidemics that affect populations concurrently or sequentially and often compound disease burden and intensify health crises. Last year, the U.S. saw not only the continuation of overlapping epidemics of HIV, COVID, and opioid misuse, but also marginalized populations affected by meningococcal disease and, to a much greater extent, mpox.

Taking an Early Lead on Mpox

amfAR helped guide the U.S. response to mpox (formerly known as monkeypox) and sound the alarm about the risk of acquiring the virus among those who comprised the majority of cases: gay, bisexual, and other men who have sex with men (MSM), particularly Black and Latino MSM as well as individuals living with HIV.

In the spring of 2022, the public policy office was a co-presenter with the White House National Monkeypox Response Deputy Coordinator Demetre Daskalakis, M.D., M.P.H., during multiple high-level meetings. In July, amfAR staff also partnered with the O'Neill Institute at Georgetown Law to publish a call to action to address the outbreak as a public health emergency: *Monkeypox and Meningococcal Disease Outbreaks Signal New Health Threats for Communities Heavily Impacted by HIV and Demand Immediate Action*. In that policy brief, amfAR included a modeling analysis that predicted mpox diagnoses in the U.S. would increase to 11,311 by August 4. Eight days after the original projection, the cases had risen to


11,177, underscoring the two institutions' prescient sense of urgency. amfAR and the O'Neill Institute followed up with two supplemental briefs, *Tackling MPX in Black and Latino Communities* and *MPX Research Gaps: What Remains Unknown*.

In *The BMJ*, amfAR staff published an article titled *What can we learn from the first 100 days of the monkeypox outbreak?* The piece described a plan of action for addressing the public health threat, including filling key knowledge gaps to stem transmission, anticipating how the pandemic may unfold, and transitioning from discussions around a new global public health architecture to its implementation.

Along with delivering presentations for policy makers and community advocates, amfAR's Greg Millett, MPH, Vice President and Director of Public Policy, co-authored two editorials in leading peer-reviewed scientific journals, *The BMJ* and *American Journal of Public Health*. In addition, the policy team was interviewed by Reuters, NPR, and NBC News about the mpox outbreak.

On the research front, amfAR awarded seed funding to two survey-based studies to assess the impact of mpox on MSM in New York City, the epicenter of the U.S. outbreak, and develop targeted interventions.

14-FOLD INCREASE IN A MONTH: PROJECTED VS. ACTUAL GROWTH IN MPX DIAGNOSES



Big Ideas Brief, *Monkeypox and Meningococcal Disease Outbreaks Signal New Health Threats for Communities Heavily Impacted by HIV and Demand Immediate Action*, July 18, 2022, available <http://bit.ly/USHIVpolicyproject>.

In a policy brief, amfAR and the O'Neill Institute at Georgetown Law correctly predicted the sharp rise in mpox cases.





"We still have a long way to go to bring the epidemic in the U.S. under control, especially among gay men and communities of color."

– Greg Millett, amfAR Vice President and Director of Public Policy



ENDING THE HIV EPIDEMIC IN THE U.S.

While responding to newer public health emergencies, amfAR continued its data-driven advocacy of rational and compassionate HIV/AIDS-related public policy by engaging in efforts to secure necessary increases in funding for HIV/AIDS research and global HIV/AIDS programs, expand access to treatment and care for marginalized populations, advocate harm reduction policies aimed at reducing the transmission of HIV and hepatitis C (HCV) among people who inject drugs, and protect the civil rights of all people affected by or vulnerable to HIV/AIDS.

Throughout the year, amfAR worked closely with members of the Biden administration, the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Department of Health and Human Services (HHS) to promote an evidenced-based response to the U.S. HIV epidemic and discuss policy initiatives.

In 2019, President Trump announced a plan to end HIV transmissions in the U.S. by 2030. The Ending the HIV Epidemic (EHE) initiative aims to reduce HIV infections by 75% in five years, and by 90% in ten years. To help policymakers, public health officials, advocates, and other stakeholders understand the opportunities and challenges across EHE jurisdictions, amfAR maintains a free interactive database (ehe.amfar.org) that includes demographic, policy, and service provider information, and epidemiological indicators.

HIV and the Opioid Epidemic


amfAR's Opioid & Health Indicators Database (opioid.amfar.org) is a free web platform designed

to support lawmakers, communities, and advocates in making informed decisions about the opioid epidemic and its impact on HIV and hepatitis C. It provides local to national statistics using reliable data sources on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange services.

EXPANDING GLOBAL HEALTHCARE ACCESS

amfAR maintains an active role in global advocacy and policy initiatives, and policy staff participate in PEPFAR Country Operational Plan meetings (for Botswana, Cameroon, Côte d'Ivoire, Eswatini, Kenya, Malawi, South Africa, Tanzania, Zambia, and Zimbabwe), the Global Fund partnership forum, and the UN High-Level Meetings on HIV/AIDS.

amfAR engages in advocacy with House and Senate appropriations committees to secure strong global HIV budgets and closely track and respond



amfAR conducted a three-day community-led monitoring workshop for nine countries in sub-Saharan Africa.

to new global health policies. Additionally, amfAR plays a key role as a technical assistance provider for in-country community-led monitoring efforts in four countries. In this role, amfAR engages with local activists and data collection teams to ensure high-quality data are produced for HIV service quality monitoring and advocacy initiatives.

amfAR conducted a three-day training workshop in South Africa for community-led monitoring programs in South Africa, Botswana, Côte d'Ivoire, Tanzania, Zimbabwe, Cameroon, Eswatini, Kenya, Malawi, and Zambia. In the U.S., the team also met with Office of Global AIDS Coordinator staff on best practices on community-led monitoring funding and project structures.

In August 2022, amfAR staff published a pair of articles in academic journals with far-reaching policy implications:

- **Telehealth Services: Implications for Enhancing Sexually Transmitted Infection Prevention** in the journal *Sexually Transmitted Diseases*. The authors presented considerations for telehealth and how it can contribute to increasing health equity by offering an important complement to and, in some cases, substitute for in-person STI services for some populations.
- In **Competing health risks associated with the COVID-19 pandemic and early response: A scoping review**, published in *PLoS One*, the authors analyzed the early impact of COVID-19 on HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.

In June, the policy team produced a major report, *Blinded by Our Own Data—Recency Testing in PEPFAR*, that outlined the technical and sometimes ethical limitations of PEPFAR's well-intentioned strategy to respond to new transmission "hot spots." In the same month, amfAR released *Key Populations, Size Estimates, and Plans in COP22*, which points out the ways in which the sizes of key populations are underestimated and provides guidance about how best to address the resulting funding discrepancies.

Empowerment Through Data

In addition to the Opioid & Health Indicators and EHE databases, amfAR maintains a suite of free interactive databases that are invaluable resources

for individuals and organizations working to secure and monitor HIV-related funding and tailor programs to meet the needs of clients.

- **PEPFAR Monitoring, Evaluation, and Reporting (mer.amfar.org)**: Launched in December 2018, the MER database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic PEPFAR data and includes downloadable PDFs, maps, data visualizations, and district-level data.
- **PEPFAR Country/Regional Operational Plans (copsdata.amfar.org)**: A complement to the MER Database, COPS highlights planned funding by program area, country, and organization for each year that has been publicly released. The database is designed to help PEPFAR increase data transparency and general participation in the planning process. Advocates from around the world rely on these resources to easily access PEPFAR data and prepare for advocacy initiatives.
- **Key Populations and Key Population Investment Fund (KPIF) Data Project (kpdata.amfar.org)**: Launched in 2021, the Data Project compiles available data on key populations demographics, epidemiology, funding, and programming from UNAIDS, PEPFAR, and the Global Fund. This resource includes country factsheets showing how funding has evolved over time, and, where possible, identifies who is responsible for implementing KP programming in PEPFAR.

International Conferences

amfAR participated in the 2022 International AIDS Conference in Montreal, Canada, the world's largest conference on HIV and AIDS. amfAR staff authored nine abstracts, covering topics such as transgender inclusion in HIV national strategies, the use of community-led monitoring in South Africa and Malawi, and the quality and implications of PEPFAR's performance targets. amfAR also sponsored a satellite session on the invisibility of transgender populations in national strategic plans for HIV/AIDS.

amfAR staff also delivered presentations to the National Association of State and Territorial AIDS Directors (NASTAD) annual meeting, the Southern African Development Community (SADC), and the NIH-funded Adolescent Trials Network, among others. Public policy staff also delivered a plenary address on lessons learned from AIDS activism for the Chan Zuckerberg Foundation.

TREAT ASIA → → →

In the Asia-Pacific region, only 65% of people living with HIV are on antiretrovirals—and coverage is below 50% for one-third of its countries. People living with and at risk for HIV in the region are also challenged by co-infections such as hepatitis, tuberculosis, mental health issues, and drug use. amfAR's TREAT Asia program—a network of clinics, hospitals, and research institutions working with civil society—brings researchers, health professionals, and advocates together to improve standards of care and expand access to treatment across the region.



CHIMERA D43 fellows on a visit to amfAR's Manhattan offices, with Dr. Annette Sohn, amfAR VP and director of amfAR's TREAT Asia program (front row, second from left); TREAT Asia Director of Research Dr. Jeremy Ross (back row, left); and Katiphot Kanoknorrasade, Project Manager, Education and Training (back row, right)

The Asia-Pacific region has struggled to keep up with global efforts to end AIDS as a public health threat by 2030. For over 20 years, amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) has been working with partners across the Asia-Pacific region to expand access to treatment for HIV and related conditions such as hepatitis C (HCV) and improve standards of care. The TREAT Asia Network encompasses 21 adult and 21 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 24 publications in peer-reviewed medical journals in FY2022.

EXPANDING ACCESS TO TREATMENT AND SERVICES

In 2022, TREAT Asia worked to make services meet standards that would improve health outcomes of people living with and at risk for HIV and HCV. Two of these projects are highlighted below.

- TREAT Asia, along with three partner organizations, initiated two Community Treatment Observatories (CTOs) in India and Indonesia to explore how HIV and HCV services could be improved and expanded. The project was implemented with the International Treatment Preparedness Coalition as a technical partner, which assisted in training the two national partners—Community Network for Empowerment (CoNE) in Manipur, India, and Peduli Hati in Indonesia—and TREAT Asia staff.

Country-specific quantitative and qualitative indicators on HIV and HCV services were developed for the CTOs. Collated in a report, the data collected focused on the state of HIV and HCV programs, treatment procurement systems, drug stocks, and diagnostics facilities that test for viral load and for common co-infections and opportunistic infections.

- leDEA Dolutegravir Resistance Study, a new global study led by the International epidemiology Databases to Evaluate AIDS (see page 21), aims to determine patterns and risk factors for virologic failure in adults on dolutegravir (DTG)-based ART, and to investigate correlations between resistance genotypes across HIV-1 subtypes. The study is planned in five leDEA Asia-Pacific network sites in Cambodia (1), Thailand (2) and Vietnam (2).

TREAT ASIA AND NETWORK PARTNER RESEARCH

TREAT Asia and its network partners conduct a myriad of studies, which this year included research focused on lung cancer, lung impairment in HIV and TB, mental health screening and linkage to care strategies, serology of SARS-CoV-2, chemsex in young men who have sex with men (MSM), and HPV and anal cancer risk among MSM, among others. Highlights include:





Left to right; Dr. Annette Sohn, amfAR VP and director of amfAR's TREAT Asia program; Dr. Tavitiya Sudjaritruk (CMU), principal investigator of the S-BETAH study; and Tulathip Suwanlerk, TREAT Asia's project manager, pediatric program



leDEA Tuberculosis Sentinel Research Network

(leDEA TB-SRN): The global study aims to describe clinical and treatment outcomes of pulmonary TB and provide a platform for global TB research among people with and without HIV. Three leDEA Asia-Pacific sites will participate: NCHADS (Kampong Cham Hospital), Cambodia, and National Hospital of Tropical Diseases and National Hospital 74, Vietnam.

leDEA Sentinel Research Network (leDEA SRN):

The global study will assess liver, cardio-metabolic, mental health, and substance use comorbidities among people with HIV over 40 years of age, on ART for more than six months. It is being implemented at two leDEA Asia-Pacific sites: BJ Medical College in Pune, India, and National Hospital of Tropical Diseases in Hanoi, Vietnam.

The Southeast Asia Transgender Cohort Study

(SEATrans): The regional prospective cohort study will enroll 450 transgender participants with and without HIV across four sites in the Philippines, Thailand and Vietnam to 1) track physical and mental health among transgender people; 2) identify biomedical, structural, and psychosocial factors impacting physical and mental health; 3) describe structural barriers to healthcare; and 4) develop guidance on holistic healthcare policies for transgender people.

Suicidal behavior among Thai adolescents living with HIV (S-BETAH): This prospective cohort study aims to determine the prevalence of mental health

disorders and suicidal behavior following positive screening and linkage to mental health services. With the first phase completed, the second phase will assess the prevalence and incidence of suicidality among this population compared with their HIV-negative age- and sex-matched counterparts. Factors associated with suicidality also will be identified.

Home-Based PrEP for Youth: Enhancing HIV Prevention for Young MSM and Transgender Women:

This three-year prospective cohort study aims to evaluate safety, acceptability, and adherence to home-based daily oral PrEP and point-of-care urine tenofovir test for monitoring PrEP adherence, among young MSM and transgender women. The study plans to enroll 75 participants at the Silom Community Clinic in Bangkok.

INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH

In 2019, the U.S. National Institutes of Health awarded a five-year, \$1.4 million grant to TREAT Asia and Columbia University to establish an innovative platform for integrating HIV, mental health, and implementation science research in the Asia-Pacific region. The objective of the CHIMERA program (Capacity development for HIV and

mental health research in Asia) is to address the dual and interlinked burdens of HIV and mental health.

Co-led by Principal Investigators Dr. Annette Sohn, amfAR vice president and director of TREAT Asia, and Dr. Milton Wainberg of Columbia University and the New York State Psychiatric Institute, the program aims to build a team within the Asia-Pacific with the capacity to lead regional HIV-mental health-implementation science research that will inform public health policy and improve clinical care for people living with HIV.

CHIMERA creates the opportunity to bring together stellar training faculty from academic centers and public health and development agencies within the region and across the world, and builds on existing NIH-funded mental health research being conducted through leDEA Asia-Pacific.

In the first half of 2022, a D43 abstract mentorship program for the Asia-Pacific AIDS & Co-Infections Conference was arranged to support CHIMERA and other Asia D43 fellows. Four Class I and one Class 2 fellows developed abstracts for submission to the June conference and all were accepted. Throughout the year, fellows continued implementation of their pilot research projects, with major strides made in data collection, data coding, and preliminary analysis. In September, 14 fellows participated in the amfAR-Columbia Research Institute training program, traveling to New York City for a weeklong slate of workshops and seminars.

IMPROVING HEALTH THROUGH INFORMATION

International AIDS Database

TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (leDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases.

TREAT Asia HIV Observational Database (TAHOD)

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which

230 children
die from
AIDS-related
illnesses

EVERY
DAY

included anonymous data from more than 10,700 patients at 21 clinical sites in 12 countries in its final data transfer in September 2021. Analysis continued through FY2022. The first TAHOD-CC (Continuum of Care) data transfer began in September 2021 and is still ongoing.

The information gathered in the database has informed the development of more effective research and treatment programs and helped define treatment standards specific to HIV/AIDS in Asia.

TAHOD Low-Intensity Transfer

Launched in 2014, TAHOD Low-Intensity Transfer (TAHOD-LITE) contained data from over 51,000 HIV-positive patients across 11 TREAT Asia network sites in its final data transfer in 2021. Analysis continued through FY2022. As an extension of TAHOD, TAHOD-LITE aimed to increase the scope of adult data collection by gathering a subset of core variables from the entire cohort of people living with HIV who have sought care at selected TAHOD sites.

TREAT Asia Pediatric HIV Observational Database

The TREAT Asia Pediatric HIV Observational Database (TAPHOD) is a regional pediatric HIV study set up by TREAT Asia in 2006. It was modeled after the adult database and includes data from more than 7,500 children and adolescents at 21 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

RESPONDING TO COVID-19

TREAT Asia continued to collate data about adults and children impacted by COVID-19. COVID-19 data on nearly 600 cases were transferred to TAHOD by 8 participating sites in late 2021. An analysis on COVID-19 clinical presentations and outcomes among PLHIV is being conducted. For the pediatric database, 11 sites are participating in COVID-19 data collection.





Launched in 2021, TREAT Asia's COVID website—www.covid19asiainfo.org—continued to be an important source of information on COVID vaccines and therapeutics relevant to the Asia-Pacific region.

International AIDS Conference and Other Conferences

TREAT Asia had a strong presence at the 2022 International AIDS Conference in Montreal, Canada. Dr. Sohn and network investigator Rena Janamnuysook co-presented "Nothing about us without us: Community-led responses and research," a study that analyzed the integration of a peer-led depression screening and linkage-to-care

intervention among transgender women living with and at risk for HIV in Bangkok. Numerous TREAT Asia partner investigators and affiliates also gave poster presentations at the conference.

TREAT Asia also participated in: the 24th Bangkok International Symposium on HIV Medicine in January 2022; the Conference on Retroviruses and Opportunistic Infections in February; the PEPFAR Regional Operational Plan Virtual Planning Meetings (Asia Region) in May; the World Hepatitis Summit and the Asia Pacific AIDS & Co-Infections Conference, both in June; and the International Workshop on HIV Pediatrics 2022 in July.



"In general, health disparities among transgender women and men are caused by a range of factors, including stigma and discrimination, violence, and poor mental health."

– Rena Janamnuysook, MBA, TREAT Asia network investigator and co-investigator of the SEATrans study

PUBLIC → → → → INFORMATION

In this age of social media, misinformation, conspiracy theories, and fragmented news media, amfAR remains a steadfast and authoritative source of news and information on HIV/AIDS. With an ever-increasing number of causes and organizations competing for attention, keeping HIV in the public consciousness can be challenging. To address that challenge, amfAR employs every platform and avenue available to sustain public awareness of HIV and support for the fight against AIDS.

amfAR translates and disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research on HIV.

EDUCATIONAL MATERIALS

amfAR produces periodicals in both print and digital formats, including its newsletter, *Innovations*, published twice a year and distributed to about 18,000 people, and a monthly e-mail newsletter, *Insights*, distributed to approximately 10,000.

The Foundation's website—www.amfar.org—features news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. In April 2022, amfAR relaunched its website—faster-loading pages, easier navigation, desktop- as well as mobile-friendly, and increased stickability (users are staying 20% longer than before). The website attracts an average of 25,000 visitors per month.

amfAR creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public. amfAR's Public Information team also works closely with the Public Policy Office and TREAT Asia staff to produce a wide range of issue briefs, facts sheets, infographics, and reports (see above).

SOCIAL MEDIA

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation has expanded its social platforms to include TikTok, targeting the new generation of advocates. amfAR regularly updates its social channels with the latest research breakthroughs and policy news, as well as

amfAR has over

 **185,000** followers

 **118,000** followers

 **82,000** followers

 **43,000** followers

detailed coverage from its world-renowned fundraising galas.

amfAR has over 82,000 followers on Facebook, more than 43,000 X (formerly Twitter) followers, over 118,000 TikTok followers, and 185,000 Instagram followers. Across all social media platforms, audience increased by 44% in 2022 and total impressions increased 43%.

One example of the power of social media to amplify important issues and to rapidly disseminate information is an issue brief on controlling the growing mpox outbreak co-authored by amfAR and released in July. The communications team developed messaging to promote the brief's recommendations and created shareable visual tools that were promoted across amfAR's social media channels. In addition, a short video featuring amfAR VP and Director of Public Policy Greg Millett was created and shared on TikTok and Reels to communicate the issue brief's key recommendations.

While the first months of the outbreak were marked by various messaging complications, with U.S. public health authorities reticent to speak plainly on risk and harm reduction, amfAR's experts spoke in direct terms and called attention to issues of equity and treatment access that also plagued the U.S. response to HIV and COVID-19.

MEDIA OUTREACH

In FY2022, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including NBC News, CNN, NPR, Associated Press, Reuters, *The New York Times*, *The Washington Post*, *USA Today*, *U.S. News & World Report*, *The Hill*, *The Boston Herald*, *The Boston Globe*, *Nature*, *Science*, *The BMJ*, *Vanity Fair*, *Vogue*, *People*, *Variety*, *CR Fashion Book*, *POZ*, *Women's Wear Daily*, *Us Weekly*, *The Hollywood Reporter*, *Deadline*, *Yahoo*, *Page Six*, *Daily Mail*, *Wired*, *Forbes*, and *The Daily Beast*.

In July 2022, amfAR's communications team attended the XXIV International AIDS Conference and provided on-the-ground coverage for social media and amfAR's website. The communications team also assisted in the promotion of a satellite event hosted by amfAR's Public Policy Office, disseminating social media content and ensuring media coverage.

BENEFIT EVENTS

Public Information assisted in the production of benefit events such as *From the Studio Part III*, an art auction in partnership with Christie's in May 2022, as well as fundraising galas in Dallas, Texas, in October 2021; Los Angeles, California,

in November 2021; Palm Beach, Florida, in March 2022; Cannes, France, in May 2022; and Venice, Italy, in September 2022.

CELEBRITY SUPPORT

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR from prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing support of celebrities from all over the world.

Celebrity supporters included Casey Affleck, Christina Aguilera, Matteo Bocelli, Rachel Brosnahan, Steve Buscemi, Naomi Campbell, Charli XCX, Patricia Clarkson, Robert De Niro, Jay Ellis, Edward Enninfu, Cynthia Erivo, Ellie Goulding, Heather Graham, Tiffany Haddish, Regina Hall, Emily Hampshire, Tom Hanks, Tommy Hilfiger, Vanessa Hudgens, Kate Hudson, Milla Jovovich, Nicole Kidman, Heidi Klum, Laura Linney, Julian Lennon, Eva Longoria, Baz Luhrmann, Madonna, Ricky Martin, Kacey Musgraves, Rita Ora, Katy Perry, Billy Porter, Michaela Jaé Rodriguez, Michelle Rodriguez, Carine Roitfeld, Nina Senicar, Sylvester Stallone, Marisa Tomei, Ellen von Unwerth, Michelle Williams, Rita Wilson, and Michelle Yeoh.



The live auctions at amfAR's benefit galas raise critical funds for AIDS research.

**GRANTS,
FELLOWSHIPS,
AWARDS**

2022 RESEARCH GRANTS AND FELLOWSHIPS

All projects below were awarded funding during the period October 1, 2021 through September 30, 2022.

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Multiplex gene editing of hematopoietic cells to eradicate the viral reservoir
Saar Gill, MD, PhD
University of Pennsylvania
Philadelphia, PA
\$180,000

Gene expression from AAV vectors in the presence of ART
Keith Jerome, MD, PhD
University of Washington
Seattle, WA
\$148,514

Characterizing loss or eradication of activatable reservoir (CLEAR) in PLHIV
Xu Yu, MD
Massachusetts General Hospital
Boston, MA
\$1,000,000

Multi-armed anti-HIV immunity by CAR-engineered HSCs
Anjie Zhen, PhD
University of California, Los Angeles
Los Angeles, CA
\$210,000

TARGET GRANTS

Eradication of HIV-1 reservoir in germinal center T follicular helper cells
Qigui Yu, MD, PhD
Indiana University
Indianapolis, IN
\$100,000

Induction of autophagy to enhance CAR-T therapy for HIV elimination
Anjie Zhen, PhD
University of California, Los Angeles
Los Angeles, CA
\$100,000

MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

Protein pre-exposure for the induction of immune tolerance toward AAV vector-mediated anti-HIV antibody delivery
Sebastian Fuchs, PhD
University of Miami
Coral Gables, FL
\$150,000

Role of glutaminolysis in HIV persistence and associated inflammation
Leila Giron, MSc, PhD
The Wistar Institute
Philadelphia, PA
\$150,000

Defining the mutational landscape of HIV capsid sensitivity to TRIM5 to uncover TRIM5's antiviral mechanism
Jeannette Tenthorey, PhD
Fred Hutchinson Cancer Center
Seattle, WA
\$150,000

2022 TREAT ASIA GRANTS AND AWARDS

All projects below were awarded funding during the period October 1, 2021 through September 30, 2022.

¹Supported by U.S. National Institutes of Health federal award number U01AI069907, with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, the National Heart Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Cancer Institute, the National Institute of Mental Health and the Fogarty International Center.

²Supported by U.S. National Institutes of Health federal award number D43TW011302, funded by the Fogarty International Center and the National Institute of Mental Health.

³Supported with funds provided by ViiV Healthcare.

AUSTRALIA

University of New South Wales
Sydney
Matthew G. Law, PhD
leDEA Asia-Pacific Research Collaboration: Data Management and Analysis Center
\$494,813¹

AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) SITES

Clinic 87, Sunshine Coast Hospital and Health Service
Birtinya
David Sowden, MBBS
\$9,875¹

Cairns and Hinterland Hospital and Health Service (CHHHS)
Cairns
Darren Russell, MD
\$9,775¹

RPA Sexual Health, Sydney Local Health District
Camperdown
David Templeton, PhD
\$9,725¹

Melbourne Sexual Health Centre
Carlton
Richard Teague, MBBS (Monash Uni), FRACGP, FRChSHM.
\$6,750¹

Monash Medical Centre
Clayton
Ian Woolley, MBBS, FRACP
\$11,500¹

Lismore Sexual Health and AIDS Services (SHAIDS), Northern NSW Local Health District
Lismore
Natalie Edmiston, MBBS, MPH
\$10,300¹

Victorian HIV Service, Department of Infectious Diseases, The Alfred Hospital
Melbourne
Jennifer Hoy, MBBS
\$11,100¹

Prahran Market Clinic Pty Ltd
Prahran
Norman Roth, MBBS FChSHM
\$9,800¹

Gold Coast Hospital and Health Service
Southport
Caroline Thng, MBBS, MRCP
\$10,500¹

East Sydney Doctors
Sydney
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
\$8,425¹

Holdsworth House Medical Practice
Sydney
Mark Bloch, MD
\$10,300¹

St. Vincent's Hospital Sydney Limited
Sydney
Andrew Carr, MD
\$10,300¹

Taylor Square Private Clinic
Sydney
Robert Finlayson, FChSHM, DipVen, MBBS
\$5,650¹

Western Sydney Local Health District
Westmead
Rohan Bopage, MBBS, FRACP, MMed STD/HIV, FChSHM
\$6,025¹

CAMBODIA

[National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health](#)
Phnom Penh
Vohith Khol, MD, MSc
The TAHOD Continuum of Care (TAHOD-CC) Study
\$21,500¹

leDEA Tuberculosis Sentinel Research Network (TB-SRN)
\$44,911 (2021-2022)¹ ; \$59,175 (2022-2023)¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$25,000¹

CHINA

[Queen Elizabeth Hospital](#)
Hong Kong
Man Po Lee, MBBS
The TAHOD Continuum of Care (TAHOD-CC) Study
\$22,500¹

INDIA

[The Voluntary Health Services, VHS Infectious Diseases Medical Centre](#)
Chennai
Nagalingeswaran Kumarasamy, MD, MBBS, PhD
The TREAT Asia Observational Database (TAHOD) Study
\$29,000¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$4,000¹

[Wide Angle Social Development Organization \(WASDO\)](#)
Imphal
Montu Ahanthem
Establishing a community treatment observatory for providing and improving quality HIV and HCV service delivery
\$10,880³

[Community Network for Empowerment \(CoNE\)](#)
Imphal West
Rajkumar Nalinikanta
Establishment of a community treatment observatory as a model for providing and improving HIV & HCV service delivery
\$13,800³

Towards mirco elimination: Hepatitis C same day test and treat among PLHIV and PWID
\$5,000

[BJ Medical College & Sassoon General Hospitals](#)
Pune
Rohidas T Borse, MD, MBBS
The TREAT Asia Observational Database (TAHOD) Study
\$22,000¹

leDEA Sentinel Research Network (SRN)—Asia-Pacific
\$72,765¹

Lung Morbidity Study
\$43,893 (2021-2022)¹; \$44,593 (2022-2023)¹

Aarti Kinikar, MD, DCH, DNB, MRCP
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$4,000¹

[Institute of Infectious Diseases](#)

Pune
Sanjay Pujari, MD, AAHIVS, MBBS
The TREAT Asia HIV Observational Database (TAHOD) Study
\$27,000¹

INDONESIA

[Hasan Sadikin General Hospital](#)
Bandung
Anggraini Alam, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

[Faculty of Medicine, Udayana University - Prof. Dr. I G. N. G. Ngoerah Hospital](#)
Denpasar
I Ketut Agus Somia, SpPD, KPTI, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC) Study
\$21,500¹

Ketut Dewi Kumara Wati, MD, PhD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

[Cipto Mangunkusumo General Hospital](#)
Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$8,500¹

Evy Yuniastuti, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC) Study
\$22,000¹

Behavioral Economic Approaches for Tuberculosis Preventive Therapy in Asia Pacific leDEA (BEAT TB ASIA)
\$18,576¹

[Yayasan Peduli Hati Bangsa](#)
Pagedangan
Claudius Novchovick Mone Iye
Establishment of community treatment observatory as a model for providing and improving HIV & HCV service delivery
\$12,000³

JAPAN

[National Center for Global Health and Medicine](#)
Tokyo
Junko Tanuma, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC) Study
\$14,000¹

MALAYSIA

[University of Malaya Medical Center](#)
Kuala Lumpur
Raja Iskandar Shah Raja Azwa, FRCP, Dip HIV, MBChB
The TAHOD Continuum of Care (TAHOD-CC) Study
\$21,500¹

[Sungai Buloh Hospital](#)
Sungai Buloh
Yasmin Mohamed Gani, M.D.
The TAHOD Continuum of Care (TAHOD-CC) Study
\$16,000¹

PHILIPPINES

[LoveYourself \(VINN Advocacy for the LGBT-MSM\), Inc.](#)
Mandaluyong City
Ronivin Garcia Pagtakhan, MD, PhD
Southeast Asia Transgender Cohort Study (SEATrans)
\$16,092¹

[Research Institute for Tropical Medicine](#)
Muntinlupa City
Virginia Aguilar, MD, MPH
Behavioral Economic Approaches for Tuberculosis Preventive Therapy in Asia Pacific leDEA (BEAT TB ASIA)
\$20,088 (2021-2022)¹; \$19,764 (2022-2023)¹

Rossana Ditangco, MD
The TAHOD Continuum of Care (TAHOD-CC) Study
\$16,500¹

Adolescent and Young Adult network of leDEA (AYANI) Study
\$18,407¹

SINGAPORE

Tan Tock Seng Hospital

Oon Tek Ng, MBBS, MRCP, MMed, MPH
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$12,000¹

SOUTH KOREA

University-Industry Foundation, Yonsei University Health System

Seoul
Jun Yong Choi, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$21,500¹

TAIWAN

Taipei Veterans General Hospital

Taipei
Hsin-Pai Chen, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$13,000¹

THAILAND

Chulalongkorn University

Bangkok
Thanyawee Puthanakit, MD
Adolescent and Young Adult network of leDEA
(AYANI) Study
\$11,506 (2021-2022)¹; \$22,092 (2022-2023)¹

Pongkwan Yimsaard, MD
CHIMERA Implementation Science Pilot Research
Project
\$8,000²

HIV-NAT / Thai Red Cross AIDS Research Centre

Bangkok
Anchalee Avihingsanon, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$21,500¹
Mental health and HIV service integration in
Asia (MHint)
\$17,647¹

Kiat Ruxrungtham, MD, MSc
Thailand National Health Registries Study
\$19,000¹

Institute of HIV Research and Innovation Foundation (IHRI)

Bangkok
Nittaya Phanuphak, MD, PhD
Anal HSIL screening algorithm optimization study
\$47,093¹

Chemsex in young MSM: Comprehensive
assessment in a Longitudinal study on Young
MSM Attracting to chemseX (CYLMAX)
\$13,065¹

Mental health and HIV service integration in
Asia (MHint)
\$17,647¹

Southeast Asia Transgender Cohort Study
(SEATrans)
\$24,735¹

Rainbow Sky Association of Thailand

Bangkok
Phubet (Kao) Panpet, MSc
The South- East Asian Transgender Health Cohort
\$16,106¹

Ramathibodi Hospital, Mahidol University

Bangkok
Sasisopin Kiertiburanakul, MD, MHS
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$21,500¹

Chiang Mai University Research Institute for Health Sciences

Chiang Mai
Linda Aupibul, MD
Thai Program to Actively follow Perinatal
Adolescents and Young Adults living with HIV
(Thai-PAPAYA) Coordinating Center
\$11,036 (2021-2022)¹; \$8,829 (2022-2023)³

Romanee Chaiwarith, MD, MHS
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$16,000¹

Tavitiya Sudjaritruk, MD, ScM PhD
Suicidal Behavior Among Thai adolescents living
with HIV (S-BETAH) study
\$20,242 (2021-2022)¹; \$47,731 (2022-2023)¹

Adolescent and Young Adult Network of leDEA
(AYANI) Study
\$21,887¹

Chiangrai Prachanukroh Hospital

Chiang Rai
Suwimon Khusuwan, MD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$23,000¹

Pradthana Ounchanum, MD
Suicidal Behavior Among Thai adolescents living
with HIV (S-BETAH) study
\$11,533¹

Srinagarind Hospital, Khon Kaen University

Khon Kaen
Pope Kosalaraksa, MD
Suicidal Behavior Among Thai adolescents living
with HIV (S-BETAH) study
\$16,956¹

USA

National Foundation for the Centers for Disease Control and Prevention, Inc.

Atlanta
Joseph Woodring, DO, MPH, MTM&H
Home-Based PrEP for Youth: Enhancing HIV
Prevention for Young Men who have Sex with
Men and Transgender Women
\$92,876 (2021-2022)¹; \$336,660 (2022-2025)¹

Johns Hopkins University

Baltimore
Amita Gupta, MD, MHA
leDEA Asia-Pacific: JHU/BJGMC cohort and
substudies
\$238,991¹

Research Foundation for Mental Hygiene, Inc. Menands

Claude Ann Mellins, PhD
Technical support to the Suicidal behavior among
Thai adolescent living with HIV (S-BETAH) study
\$13,915(2021-2022)¹; \$19,973 (2022-2023)¹

Columbia University

New York
Milton Wainberg, MD
Mental health and HIV service integration in Asia
(MHint)
\$29,528¹
(2021-2022); \$18,934¹ (2022-2023)

Capacity development for HIV and mental health
research in Asia (CHIMERA)
\$31,890²

VIETNAM

Bach Mai Hospital

Hanoi
Do Duy Cuong, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$21,500¹

National Hospital of Pediatrics

Hanoi
Nguyen Van Lam, MD, MSc
TREAT Asia Pediatric HIV Observational Database
(TApHOD) Site
\$20,000¹

National Hospital of Tropical Diseases

Hanoi
Thach Ngoc Pham, MD, PhD
The TAHOD Continuum of Care (TAHOD-CC)
Study
\$22,500¹

leDEA Sentinel Research Network (SRN)—
Asia-Pacific
\$51,066 (2021-2022)¹; \$82,854 (2022-2023)¹

leDEA Tuberculosis Sentinel Research Network
(TB-SRN)
\$29,911¹

Children's Hospital 1
Ho Chi Minh City
Du Tuan Quy, MD
TREAT Asia Pediatric HIV Observational Database
(TApHOD) Site
\$20,000¹

Children's Hospital 2
Ho Chi Minh City
Nguyen Dinh Qui, MD
TREAT Asia Pediatric HIV Observational Database
(TApHOD) Site
\$20,000¹

National Hospital 74
Phuc Yen City
Dien Quang Vu, MD
The leDEA Tuberculosis Sentinel Research
Network (TB-SRN) study
\$35,375 (2021-2022)¹; \$41,326 (2022-2023)¹

2022 PUBLIC POLICY GRANTS AND AWARDS

The projects listed below were awarded funding during the period October 1, 2021 through September 30, 2022.

¹Supported with funds provided by the Elton John AIDS Foundation

²Supported with funds provided by ViiV Healthcare

Improving Trans Inclusion in National Strategic Plans for HIV/AIDS

Project Director: Erika Castellanos
Global Action for Trans Equality (GATE, Inc.)
New York, NY
\$105,707¹

KPIF Zambia—Building community power and sustaining impact of KPIF in Zambia

Project Director: Justine MacWilliam
AIDS Vaccine Advocacy Coalition (AVAC)
\$80,464²

Accountability for Kenya's Key Populations through Community-led Monitoring

Project Director: Maureen Milanga
Health GAP (Global Access Project)
Brooklyn, NY
\$51,319

Rapid Epidemiologic Study of Prevalence, Networks, and Demographics of Monkeypox Infection (RESPND-MI)

Project Director: Keletso Makofane, PhD
PrEP4All, Inc.
Brooklyn, NY
\$20,000

2022 COMMUNITY OUTREACH AWARDS

Community Outreach Award: Dance for Life: A dance festival to fight HIV/AIDS and COVID-19
Foundation for the AIDS Monument (FAM)
West Hollywood, CA
\$15,000

FINANCIAL SUMMARY

STATEMENT OF ACTIVITIES

For the year ended
September 30, 2021

Public Support and Revenue

Public support	\$	4,188,758
Special events		15,798,781
Planned giving		3,266,597
Government funding		7,444,441
Investment income and other revenue		(6,408,741)
Total public support and revenue	\$	24,289,836


Expenses

Research	\$	9,067,686
TREAT Asia		4,381,101
Public Policy		2,169,497
Public Information		3,558,130
Total program services	\$	19,176,414

Fundraising		6,082,791
Management and general		2,556,558
Total supporting services	\$	8,639,349

Total expenses	\$	27,815,763
-----------------------	-----------	-------------------

Change in net assets		(3,525,927)
Net assets, beginning of year		38,620,279
Net assets, end of year	\$	35,094,352



EXPENSES



\$19,176,414

PROGRAM



\$6,082,791

FUNDRAISING




\$2,556,558

MANAGEMENT AND GENERAL

\$27,815,763

TOTAL EXPENSES



PROGRAM EXPENSES



\$9,067,686

RESEARCH



\$4,381,101

TREAT ASIA



\$2,169,497

PUBLIC POLICY



\$3,558,130

PUBLIC
INFORMATION

\$19,176,414

TOTAL PROGRAM EXPENSES

STATEMENT OF FINANCIAL POSITION

Assets

Cash and investments	\$ 39,505,783
Pledges and receivables, net	9,902,923
Prepaid expenses and other assets	3,341,375
Furniture, equipment, and leasehold improvements, net	2,435,956
Total Assets	\$ 55,186,037

Liabilities

Accounts payable and accrued expenses	\$ 3,431,342
Line of credit	850,000
Grants and fellowships payable, net	743,456
Deferred support and refundable advances	13,553,638
Other long-term liabilities	1,513,249
Total liabilities	\$ 20,091,685

Net assets

Net assets beginning of year	\$ 38,620,279
Change in net assets	(3,525,927)
Net assets end of year	\$ 35,094,352

Total liabilities and net assets	\$ 55,186,037
---	----------------------

LEADERSHIP AND ADVISORY COMMITTEES

BOARD OF TRUSTEES

Fiscal Year 2022

Co-Chair
T. Ryan Greenawalt
Managing Director
Ramirez & Co
New York, NY

Co-Chair
Kevin McClatchy
Chairman of the Board
The McClatchy Company
Palm Beach, FL

Secretary
Jay Ellis
Jay Ellis Foundation
Los Angeles, CA

Treasurer
Donald Dye
Chairman, Sky Lake Partners
New York, NY

TRUSTEES

Amy Andelson
Screenwriter/Author
Los Angeles, CA

Glenn Isaacson
President
Bradford Allen
New York, NY

Arthur Lewis
Partner/Creative Director
UTA Fine Arts and UTA Artist Space
Beverly Hills, CA

Michael Lorber
Senior Vice President
Douglas Elliman Real Estate
New York, NY

Laurence Milstein
Co-Founder, PRZM
New York, NY

Cindy Rachofsky
Philanthropist
Dallas, TX

Vin Roberti
Chairman
Roberti Global
Washington, DC

Jeffrey Schoenfeld
Partner
Head of Global Institutional Business
Development & Relationship Management
Brown Brothers Harriman
New York, NY

Mervyn F. Silverman, MD, MPH
President
Mervyn F. Silverman Associates
Crockett, CA

Mario Stevenson, PhD
Professor of Medicine, Chief, Division
of Infectious Diseases
University of Miami
Leonard M. Miller School of Medicine
Miami, FL

Robert L. Traynham II, PhD
Head of Public Affairs
Facebook
Washington, DC

Phill Wilson
Founder and CEO
Black AIDS Institute (retired)
Los Angeles, CA

IN MEMORIAM

Mathilde Krim, PhD
Founding Chairman

Dame Elizabeth Taylor
Founding International Chairman

Arthur J. Ammann, MD
Arlen H. Andelson
Sheldon W. Andelson, Esq
Zev Braun
Arnold W. Klein, MD
Mrs. Albert D. Lasker
Jonathan M. Mann, MD, MPH
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, MD
Peter Scott, Esq
Wallace Sheft, CPA
Tom Stoddard
Joel D. Weisman, DO

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

Lishomwa Ndhlovu, M.D., PhD
Professor
Division of Infectious Diseases
Weill Cornell Medicine

Mohamed Abdel-Mohsen, PhD*
Associate Professor
Vaccine & Immunotherapy Center
The Wistar Institute

Margaret Ackerman, PhD*
Associate Professor
Department of Microbiology and Immunology
Geisel School of Medicine
Dartmouth College

José Alcamí, M.D., PhD*
Head of AIDS Immunopathogenesis Unit
National Centre of Microbiology
Instituto de Salud Carlos III

Deborah Anderson, PhD
Professor of Medicine
Chobanian & Avedisian School of Medicine
Boston University

Warren Andiman, MD
Professor Emeritus of Pediatrics
Department of Pediatric Infectious Diseases
Yale School of Medicine

Aleksandar Antanasijevic, PhD*
Postdoctoral Research Associate
The Scripps Research Institute

Patrick Arbuthnot, MD*
Professor and Director
Wits/SAMRC Antiviral Gene Therapy Research
Unit (AGTRU)
University of the Witwatersrand

Nancie Archin, PhD*
Assistant Professor of Medicine
Division of Infectious Diseases
Department of Medicine
The University of North Carolina at Chapel Hill

Jason Brenchley, PhD*
Senior Investigator
Immunopathogenesis Section
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Dennis R. Burton, PhD
Professor
Department of Immunology
The Scripps Research Institute

Salvatore T. Butera, DVM, PhD
Chief Science Officer
Scripps CHAVI-ID
The Scripps Research Institute

Edward Campbell, PhD
Assistant Professor
Department of Microbiology and Immunology
School of Medicine
Loyola University at Chicago

Alex Carballo-Diéguez, PhD
Co-Director and Senior Research Scientist
HIV Center for Clinical and Behavioral Studies
New York State Psychiatric Institute
Columbia University

Ann Chahroudi, M.D., PhD*
Associate Director, Clinical Affairs
Medical Scientist Training Program
Associate Professor, Infectious Disease
Department of Pediatrics
School of Medicine
Emory University

David B. Clifford, MD
Professor
Department of Neurology
Washington University School of Medicine

Grant Colfax, MD
Director
Marin Health and Human Services
San Rafael, California

Deborah Jean Cotton, MD, MPH
Professor of Medicine
Boston University School of Medicine

Bryan R. Cullen, PhD, DSc
James B. Duke Professor
Department of Molecular Genetics and
Microbiology
Director, Duke University Center for Virology
Duke University Medical Center

Susanna Cunningham-Rundles, PhD
Professor Emerita of Research Immunology
Department of Pediatrics
Weill Cornell Medical College

Richard Thomas D'Aquila, MD
The Howard Taylor Ricketts Professor of Medicine
Division of Infectious Diseases
Director, Northwestern HIV Translational Research Center
Feinberg School of Medicine
Northwestern University

Gregory Del Prete, PhD*
Associate Director, Nonhuman Primate Resources
Senior Researcher
Frederick National Laboratory for Cancer Research
National Cancer Institute at Frederick (NIH)

Sherry Deren, PhD
Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, MD, MS
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, PhD
Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Daniel C. Douek, MD, PhD
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Boro Dropulić, PhD, MBA*
Executive Director
Caring Cross

D. Peter Drotman, MD, MPH
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, PhD
Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Homayoon Farzadegan, PhD
Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Sarah Fidler, BSc, MBBS, FRCP, PhD*
Professor of HIV and Communicable Diseases
Faculty of Medicine, Department of Infectious Disease
Imperial College London

Dianne M. Finkelstein, PhD
Professor of Biostatistics
Harvard School of Public Health
Director of the Cancer Center Biostatistics
Massachusetts General Hospital

Gerald Herbert Friedland, MD
Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Howard E. Gendelman, MD
Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Marit van Gils, PhD*
Associate Professor
Department of Medical Microbiology & Infection Prevention
Academic Medical Center of the University of Amsterdam

Nancy L. Haigwood, PhD
Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Alon Herschhorn, PhD*
Assistant Professor of Medicine
Division of Infectious Diseases and International Medicine
University of Minnesota

Charles H. Hinkin, PhD
Professor
Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
University of California, Los Angeles

David Ho, MD
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Ya-Chi Ho, MD, PhD*
Assistant Professor of Microbial Pathogenesis and Medicine
Microbial Pathogenesis
Yale University

Thomas J. Hope, PhD
Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Shiu-Lok Hu, PhD
Professor
School of Pharmacy
University of Washington

Nuria Izquierdo-Useros, PhD*
Principal Investigator, Researcher
AIDS Research Institute IrsiCaixa

Richard Jefferys
Basic Science, Vaccines, and Cure Project
Director
Treatment Action Group

Jonathan Karn, PhD*
Director
Center for AIDS Research
Case Western Reserve University

Mary Kearney, PhD*
Deputy Director, HIV Dynamics and Replication Program
Head, Translational Research Section
Host-Virus Interaction Branch
National Cancer Institute

Vineet KewalRamani, PhD
Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Scott Kitchen, PhD
Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Richard Kornbluth, MD, PhD
President and Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard A. Koup, MD
Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Daniel Kuritzkes, MD*
Harriet Ryan Albee Professor of Medicine
Department of Medicine
The Brigham and Women's Hospital, Inc.

Nathaniel R. Landau, PhD
Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, PhD
Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke's Medical Center

Michael Lederman, MD
Scott R. Inkley Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, DSc
Professor of Virology, Emeritus
Department of Immunology and Infectious Diseases
Harvard School of Public Health

Michael J. Leibowitz, MD, PhD
Professor, Medical Microbiology and Immunology
University of California, Davis

Robert J. Levine, MD
Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Sharon Lewin, FRACP, PhD*
Professor
Head of Department, Infectious Diseases
Director, Peter Doherty Institute for Infection and Immunity
University of Melbourne

Judy Lieberman, MD, PhD
Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

H. Kim Lyerly, MD
Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Robbie Mailliard, PhD*

Assistant Professor, Infectious Diseases and Microbiology
 Director of the MS Program, Infectious Diseases and Microbiology
 University of Pittsburgh

David M. Margolis, MD

Professor of Medicine, Microbiology and Immunology, and Epidemiology
 School of Medicine
 University of North Carolina at Chapel Hill

Martin H. Markowitz, MD

Professor and Clinical Director
 Aaron Diamond AIDS Research Center

Kenneth Hugh Mayer, MD

Infectious Disease Attending & Director of HIV Prevention Research
 Beth Israel Deaconess Medical Center
 Professor of Medicine
 Harvard Medical School
 Medical Research Director, Co-Chair
 The Fenway Institute/Fenway Health

Joseph M. McCune, MD, PhD

Professor Emeritus of Medicine
 Department of Medicine
 University of California, San Francisco

Donna Mildvan, M.D.

Chief, Division of Infectious Diseases
 Department of Medicine
 Beth Israel Medical Center

Walter Mothes, PhD*

Professor of Medicine
 Professor of Microbial Pathogenesis
 Co-Leader, Cancer Microbiology
 Yale University

Thumbi Ndung'u, BVM, PD*

Professor
 Director, HIV Pathogenesis Programme
 Director, Consortium Steering Committee
 Member & Site Principal Investigator
 SANHE Programme
 African Health Research Institute, KwaZulu-Natal,
 South Africa

Jay A. Nelson, PhD

Professor and Director
 Vaccine and Gene Therapy Institute
 Oregon Health and Science University

Douglas Nixon, M.D., PhD*

Professor of Immunology in Medicine
 Weill Medical College of Cornell University

Nancy Padian, PhD, MPH

Adjunct Professor of Epidemiology
 School of Public Health
 University of California, Berkeley

Savita Pahwa, MD

Professor of Microbiology and Immunology
 Professor in Pediatrics and Medicine
 Director of the Miami Center for AIDS Research
 University of Miami Leonard M. Miller School of Medicine

Hamideh Parhiz, PharmD, PhD*

Research Assistant Professor of Medicine
 Perelman School of Medicine
 University of Pennsylvania

Tristram G. Parslow, MD, PhD

William Patterson Timmie Professor and Chair
 Department of Pathology and Laboratory Medicine
 Emory University School of Medicine

Matija Peterlin, MD

Professor of Medicine, Microbiology and Immunology
 Department of Medicine
 University of California, San Francisco

Christopher Peterson, PhD*

Staff Scientist
 Fred Hutchinson Cancer Research Center

Lynn Pulliam, PhD

Professor
 Department of Laboratory Medicine and Medicine
 University of California, San Francisco
 Veterans Affairs Medical Center

Lee Ratner, MD, PhD

Professor
 Department of Medicine
 Washington University School of Medicine

Andrew Rice, PhD

Professor
 Department of Molecular Virology and Microbiology
 Baylor College of Medicine

James Riley, PhD*

Professor of Microbiology
 Associate Investigator, Abramson Family Cancer Research Center
 University of Pennsylvania

Nadia Roan, PhD*

Associate Professor
 Department of Urology
 University of California, San Francisco

Ruth M. Ruprecht, MD, PhD

Scientist, Department of Virology and Immunology
 Southwest National Primate Research Center
 Director, Texas Biomed AIDS Research Program
 Texas Biomedical Research Institute

Jonah Sacha, PhD*

Professor, VGTI-Vaccine and Gene Therapy Institute
 Professor, Oregon National Primate Research Center
 Molecular Microbiology and Immunology
 Graduate Program, School of Medicine
 Program in Molecular and Cellular Biosciences,
 School of Medicine
 Oregon Health and Science University

Frederick A. Schmitt, PhD

Professor
 Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
 Sanders Brown Center on Aging
 University of Kentucky

Gerald Schochetman, PhD

Senior Director
 Diagnostics Research
 Abbott Laboratories

Robert T. Schooley, MD

Infectious Disease Specialist
 Chief, Division of Infectious Diseases
 University of California, San Diego Health

Alex K. Shalek, PhD*

Associate Professor of Chemistry
 Massachusetts Institute of Technology

Gail Skowron, MD

Professor of Medicine
 Boston University School of Medicine

Ole Schmeltz Søgaard, MD, PhD*

Professor
 Department of Clinical Medicine–Department of Infectious Diseases
 Aarhus University

Leonidas Stamatatos, PhD

Member
 Fred Hutchinson Cancer Research Center
 Vaccine and Infectious Disease Division
 Immunology and Vaccine Development Program

Mario Stevenson, PhD

Professor of Medicine
 Chief, Division of Infectious Diseases
 University of Miami Leonard M. Miller School of Medicine

David Vlahov, PhD, RN

Professor of Nursing,
 Epidemiology, and Biostatistics
 University of California, San Francisco

David J. Volsky, PhD

Professor of Medicine and Pathology
 Icahn School of Medicine at Mount Sinai
 Director of Molecular Virology Laboratory
 Department of Medicine
 Mount Sinai St. Luke's and Roosevelt Hospitals

Thor Wagner, MD*

Assistant Professor
 Infectious Disease and Virology
 Seattle Children's Research Institute

Steven S. Witkin, Ph.D.

Professor of Immunology
 Department of Obstetrics and Gynecology
 Weill Cornell Medical College

Peter R. Wolfe, MD

Associate Clinical Professor
 David Geffen School of Medicine
 University of California, Los Angeles
 Sub-Investigator
 Ruane Clinical Research

Richard T. Wyatt, PhD

Professor of Immunology
 IAVI Center for Neutralizing Antibodies
 The Scripps Research Institute

Jun Xie, PhD*

Associate Professor
 Department of Microbiology and Physiological Systems
 UMass Chan Medical School
 University of Massachusetts

Xu Yu, MD*

Associate Professor of Medicine
 Associate Investigator, Ragon Institute of MGH, MIT and Harvard, Mass General Research Institute
 Associate Immunologist
 Division of Infectious Diseases, Brigham and Women's Hospital
 Harvard Medical School

Anjie Zhen, PhD*

Assistant Adjunct Professor
 School of Medicine
 University of California, Los Angeles

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, MD, MPH (Chairman)
President
Mervyn F. Silverman Associates, Inc.

Judith D. Auerbach, PhD
Science & Policy Consultant
Professor, School of Medicine
University of California, San Francisco

David Bloom, PhD
Chair, Dept. of Population and
International Health
Harvard School of Public Health

Tim Brown, PhD
Senior Fellow
The East-West Center

Daniel Douek, MD, PhD
Chief, Human Immunology Section
Vaccine Research Center
National Institutes of Health

Elvin H. Geng, MD, MPH
Professor of Medicine
Director, Center for Dissemination and
Implementation, Institute for Public Health
Director, Dissemination and Implementation
Research Core, Institute for Clinical and
Translational Science
Division of Infectious Diseases
John T. Milliken Department of Internal Medicine
Washington University, St. Louis

Katherine Luzuriaga, MD
Professor, Molecular Medicine, Pediatrics
and Medicine
University of Massachusetts Medical School

Kenneth H. Mayer, MD
Infectious Disease Attending & Director of HIV
Prevention Research, Beth Israel Deaconess
Medical Center, Boston

Visiting Professor of Medicine
Harvard Medical School

Medical Research Director
The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, PhD
Senior Associate, Global Health Policy Center
Center for Strategic and International Studies

Chairman of the Board, Friends of the Global
Fight Against AIDS, TB, and Malaria

Chairman of the Board
Corporate Council on Africa

Visiting Scholar, Institute for Applied Economics,
Global Health & the Study of Business Enterprise,
Johns Hopkins University

Member, The Council on Foreign Relations

Phill Wilson
Founder and CEO
Black AIDS Institute (retired)

MANAGEMENT GROUP

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, MD, MPA
Senior Policy and Medical Advisor

Kyle Clifford
Chief Development Officer

Sebastian Gheith
General Counsel

Bradley Jensen
Chief Financial Officer

Jeffrey Laurence, MD
Senior Scientific Consultant for Programs

Gregorio Millett, MPH
Vice President and Director, Public Policy

James Shackelford
Vice President and Director, Public Information

Annette Sohn, MD
Vice President and Director, TREAT Asia

CONNECT WITH US



@amfar



@amfARthefoundationforaidsresearch



@amfARofficial



@amfAR



@amfAR



[linkedin.com/company/amfAR](https://www.linkedin.com/company/amfAR)

amfAR, The Foundation for AIDS Research

NEW YORK

120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.

1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND

TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org



amfAR meets the BBB
Wise Giving Alliance's
Standards for Charity
Accountability.

